Grants and Contributions:
Title:
Development of IMSAFE, an Intramuscular Autoinjector to Control Bleeding
Agreement Number:
1033871
Agreement Value:
$80,000.00
Agreement Date:
Aug 1, 2025 - Mar 31, 2026
Description:
This project aims to develop a smaller, intramuscular autoinjector capable of delivering a concentrated formulation of tranexamic acid (TXA), a widely used antifibrinolytic for treating hemorrhage. The Firm’s current prototype can deliver up to 5 mL; however, user feedback from military and emergency responders indicates a strong preference for a more compact device. By formulating TXA at higher concentrations, the Firm has reduced the required injection volume to 2–3 mL. This enables the design of a smaller, more field-appropriate autoinjector without compromising therapeutic efficacy.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T6X 0J6
Reference Number:
172-2025-2026-Q2-1033871
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
701428310
Recipient Type:
For-profit organization
Recipient's Legal Name:
MACH32 INC.
Federal Riding Name:
Edmonton--Wetaskiwin
Federal Riding Number:
48021
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
334512